Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Hauschild

Showing results (11-20 of 342) with videos related to

Pageof 35
Sort By:
Oncology Research and Treatment|May 14, 2015
[Rationale, visions and limits of Immuno-oncology: Checkpoint inhibition as a new pillar of tumor therapy]Axel Hauschild, Peter Mohr
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 1, 2006
[Brief guideline--cutaneous neuroendocrine carcinoma (Merkel cell carcinoma]Axel Hauschild, Claus Garbe
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 26, 2019
Axel Hauschild, Dirk Schadendorf
Nature Reviews. Clinical Oncology|January 15, 2014
Melanoma in 2013: Melanoma--the run of success continuesDirk Schadendorf, Axel Hauschild
Oncology Research and Treatment|October 26, 2016
[Vorwort]Axel Hauschild, Dirk Schadendorf
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 19, 2010
Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanomaKatharina C Kähler, Axel Hauschild
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2013
Reply to K.S. Wilson et alAntoni Ribas, Axel Hauschild, Richard Kefford
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 11, 2008
Recent aspects of medical care of malignant melanomaPatrick Terheyden, Wolfgang Tilgen, Axel Hauschild
Experimental Dermatology|March 4, 2008
Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?Paul Lorigan, Tim Eisen, Axel Hauschild
The New England Journal of Medicine|April 4, 2019
Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. ReplyGeorgina V Long, Eduard Gasal, Axel Hauschild
Pageof 35

Showing results (11-20 of 342) with videos related to

Sort By:
Pageof 35
Oncology Research and Treatment|May 14, 2015
[Rationale, visions and limits of Immuno-oncology: Checkpoint inhibition as a new pillar of tumor therapy]Axel Hauschild, Peter Mohr
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 1, 2006
[Brief guideline--cutaneous neuroendocrine carcinoma (Merkel cell carcinoma]Axel Hauschild, Claus Garbe
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 26, 2019
Axel Hauschild, Dirk Schadendorf
Nature Reviews. Clinical Oncology|January 15, 2014
Melanoma in 2013: Melanoma--the run of success continuesDirk Schadendorf, Axel Hauschild
Oncology Research and Treatment|October 26, 2016
[Vorwort]Axel Hauschild, Dirk Schadendorf
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 19, 2010
Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanomaKatharina C Kähler, Axel Hauschild
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2013
Reply to K.S. Wilson et alAntoni Ribas, Axel Hauschild, Richard Kefford
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 11, 2008
Recent aspects of medical care of malignant melanomaPatrick Terheyden, Wolfgang Tilgen, Axel Hauschild
Experimental Dermatology|March 4, 2008
Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?Paul Lorigan, Tim Eisen, Axel Hauschild
The New England Journal of Medicine|April 4, 2019
Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. ReplyGeorgina V Long, Eduard Gasal, Axel Hauschild
Pageof 35